The latest Orlando storefront expands access to the state's widest-ranging medical cannabis inventory to patients in Central Florida
ORLANDO, Dec. 16, 2019 /CNW/ - Trulieve Cannabis Corp. (CSE: TRUL & OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, is set to open the doors of their latest Florida location on Monday, December 16th, in Orlando. The Central Florida location is a milestone for Florida's largest operator as Trulieve becomes the first licensee in Florida to surpass 40 locations.
Presently, Trulieve operates 40 other dispensaries throughout the State of Florida, including two other in the Orlando area. The storefront, located on East Colonial Drive in East Orlando, is part of the company's mission to expand and ensure safe, reliable patient access statewide.
"Trulieve's focus this year was growing strategically and expanding access throughout Central Florida is one of the ways we're doing that. Our third location in Orlando and our 41st in Florida is important as we concentrate on ensuring patients are able to access the natural, effective, and safe medications they have come to rely on," said Trulieve CEO Kim Rivers. "With a focus on delivering strong customer-centric experiences, our well-trained staff is ready to assist patients at every step of the process. Whether they are taking their first steps into medical cannabis or seeking a new treatment option, we encourage all patients to reach out to find out more."
To celebrate their newest store, Trulieve will be hosting a grand opening celebration on Monday, December 16th at 10:00 AM, with doors opening and press tours of the new dispensary immediately following. In honor of the grand opening, all patients are eligible for an in-store 25% discount at the Orlando East location on opening day.
Trulieve Orlando East Grand Opening Celebration
11291 E. Colonial Drive, Suite 121, Orlando, Florida 32817
Monday, December 16, 2019 at 10:00 AM
In stores and online, patients will find Florida's largest selection of THC and CBD products, available in a variety of delivery methods, including smokable cannabis, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients, and conveninent in-store pick-up, in addition to its 41 dispensaries in locations across the state from Pensacola to Key West.
As the state's leading medical cannabis provider, Trulieve's employees are knowledgeable and eager to help patients. Trulieve encourages potential patients as well as patients who are new to cannabis and our wide array of products to connect with the staff to learn more.
The Office of Medical Marijuana Use recently announced the registry was approaching 300,000 registered medical marijuana patients with an active ID card, with Trulieve consistently selling approximately half of the state's overall volume, per the Florida Department of Health. There are more than 2,600 registered ordering physicians in the State of Florida as well.
About Trulieve Trulieve is a vertically integrated "seed-to-sale" company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.